Codeine dispensing for privately insured children in the USA: a retrospective database study

Lucas Oliveira J e Silva, Jana L Anderson, Fernanda Bellolio, Ronna L Campbell, Molly M Jeffery

ABSTRACT
In this retrospective study using claims data from the OptumLabs Data Warehouse including 24,658,769 eligible person-years of coverage in the USA, there was substantial decline in codeine dispensing between 2010 and 2019. However, we also observed a persistence of codeine prescribing despite the FDA contraindication in 2018. In 2019, codeine was still being prescribed to children aged 12–17 years at 934 prescriptions per 100,000 person-years of coverage and 106 per 100,000 person-years of coverage in children aged <12 years.

INTRODUCTION
Codeine is a prodrug that is metabolised in the liver to morphine to produce analgesia and anti-tussive effects. The metabolism is based on the cytochrome P450-2D6 (CYP2D6) genotype, which is highly variable and can result in differing amounts of morphine produced. Even with standard dosing, ultrarapid metabolisers will produce significant morphine which may cause respiratory depression and possible death, particularly in children with a history of obstructive sleep apnea.1–3 Beginning in 2013, the US Food and Drug Administration (FDA) released increasingly restrictive warnings and ultimately recommended against the use of codeine-containing products in patients under age 18 (table 1).4 In this context, little is known about how paediatric codeine prescribing changed over time in the USA, including periods before and after the main FDA Drug Safety Communications (DSC).

METHODS
We performed a retrospective database study of privately insured children (age <18 years) who received one or more prescriptions for codeine, opioids other than codeine or non-opioid cough and cold medications between 1 January 2010 and 31 December 2019. We used pharmacy claims from the OptumLabs Data Warehouse (OLDW), a database containing over 150 million unique individuals across the USA who are privately insured and/or Medicare beneficiaries. The OLDW includes 20% of the commercially insured population in the USA, with similar distributions of age, sex and race or ethnicity to the US commercial population. This study was deemed exempt from review by the Institutional Review Board.

We used the National Drug Code Directory to categorise drugs containing codeine, opioids other than codeine and non-opioid cough and cold medications. A list of drugs evaluated in each group is available in online supplemental file 1.

RESULTS
We identified 24,658,769 eligible person-years of coverage. Codeine dispensing declined over the entire study period in both children under 12 years and those aged 12–17 years. In children<12 years, codeine dispensing decreased 97.2% (from 3,760 in 2010 to 106 per 100,000 person-years of coverage in 2019). In older children aged 12–17 years, codeine dispensing decreased 78.9% (from 4,433 in 2010 to 934 in 2019). These declines were greater than the declines in opioids other than codeine (age<12 years, declined 58.3% from 2,104 to 877; age 12–17 years, declined 61.4% from 10,439 to 4,031). They were also greater than the changes in non-opioid cough and cold medications (age<12 years, declined 52.6% from 7,980 to 3,784;
age 12–17 years, increased 39.8% from 3149 to 4400). For both age groups, the largest single-year decline in codeine dispensing was from 2017 to 2018: for children<12 years, codeine dispensing declined 61.2% (from 586 to 228); for children aged 12–17 years, codeine dispensing declined 38.1% (from 2094 in 2017 to 1295 in 2018). Figure 1 illustrates these trends. Trends of codeine prescriptions separated by pain or cough indications are available in online supplemental file 2.

**DISCUSSION**

Codeine dispensing in children has declined substantially between 2010 and 2019, including the most severe restriction in early 2018 during which the FDA made codeine contraindicated. These relative declines were specific to codeine versus other opioids and versus non-opioid cough and cold medications and were greatest in the year the most severe restriction was issued. While FDA restrictions were temporally associated with a decrease in codeine use, prescribing was already declining prior to the first DSC for both codeine and non-codeine products. In 2019, codeine was still being prescribed to children aged 12–17 years at 934 prescriptions per 100 000 person-years of coverage and 106 per 100 000 person-years of coverage in children aged<12 years. Other studies have also showed the persistence of codeine prescribing despite an absolute FDA contraindication. Efforts to

---

**Table 1** Main Food and Drug Administration (FDA) drug safety communications restricting the use of codeine in children in the USA

<table>
<thead>
<tr>
<th>Date</th>
<th>Safety announcement</th>
<th>Main evidence behind announcement*</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 February 2013</td>
<td>Boxed warning and contraindication restricting the use of codeine in postoperative pain management in children (age&lt;18 years) following tonsillectomy and/or adenoidectomy.</td>
<td>13 cases of paediatric deaths associated with codeine between 1969 and 2012 in the FDA’s Adverse Event reporting System database. Most of the cases (11/13) were reported in the setting of adenotonsillectomy (n=8) or respiratory tract infection (n=3). In most of these cases, the children appeared to receive appropriate doses of codeine. Suspicion that cytochrome P450 2D6 (CYP2D6) metaboliser status was among the reasons behind the deaths, with some of these children being characterised as ultrarapid metabolisers (rapid conversion of codeine into morphine).</td>
</tr>
<tr>
<td>20 April 2017</td>
<td>Contraindication for the use of codeine to treat pain or cough in children aged&lt;12 years. Boxed warning recommending against the use of codeine in adolescents (age 12–17 years) who are obese or have conditions such as obstructive sleep apnea or severe lung disease.</td>
<td>64 cases of respiratory depression, including 24 deaths, with codeine-containing medicines in children aged&lt;18 years. Fifty of the 64 cases (78.1%) occurred in children aged&lt;12 years. Of the 24 cases reporting death, 21 (87.5%) occurred in children aged&lt;12 years. The reasons for codeine-containing medicine use in these cases included post-tonsillectomy and/or adenoidectomy pain management, other postoperative pain, general pain, sore or strep throat pain and cough and cold. Although few cases mentioned the status of CYP2D6 genotype, ultrametabolisation remains a key suspected driver of these adverse events.</td>
</tr>
<tr>
<td>11 January 2018</td>
<td>Safety labelling changes contraindicating the use of prescription opioid cough and cold medicines containing codeine in children aged&lt;18 years.</td>
<td>After FDA review of the data and discussion with a panel of outside experts, there was a conclusion that the risks of slowed or difficult breathing, misuse, abuse, addiction, overdose and death with these medicines outweigh their benefits in patients younger than 18 years.</td>
</tr>
</tbody>
</table>

*These are based on information provided in the drug safety communications published in the FDA’s website.
cease the use of codeine in paediatric patients need to continue.

Twitter Lucas Oliveira J e Silva @lucasojesilva12

Contributors Conceptualisation: JLA, FB and MMJ. Formal analysis, methodology, project administration, supervision, validation and guarantor: MMJ. Writing—original draft: LOJS and JLA. Investigation, writing—review and editing and provided critical revision and contribution for important intellectual content: All authors.

Funding This study was in part supported by the James H. and Helen F. Crossingham Emergency Medicine Career Development Award (number TN005446), an intramural research funding given to JLA.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study was deemed exempt from review by the Mayo Clinic Institutional Review Board.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

REFERENCES


